Home › Compare › GRWXF vs ABBV
GRWXF yields 33.33% · ABBV yields 3.06%● Live data
📍 GRWXF pulled ahead of the other in Year 1
Combined, GRWXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GRWXF + ABBV for your $10,000?
Molten Ventures Plc, formerly known as Draper Esprit plc, is a private equity and venture capital firm specializing in any stage in the lifecycle of a business from seed and series A stage, growth capital to pre-IPO investments, late stage, cross-stage investments, buyouts, PIPES, and also makes direct and secondary investments in portfolio companies. It also seeks to buy entire funds from other tech investors. The firm primarily invests in companies from pre-revenue stage upwards. It primarily invests in technology oriented business. The firm typically invests in digital technology, consumer, commerce, enterprise and data, systems and semiconductors, financial technology, internet, mobile, media, telecom, consumer technology, enterprise technology, SaaS, fintech, deeptech, digital health & wellness and healthcare sectors, software, hardware, medical technology, and life sciences sectors. It invests in companies based in Europe, Ireland, and United Kingdom. The firm seeks to invest between $0.02 million and €10 million ($10.88 million) in rounds up to €1 million ($1.09 million) and €30 million ($32.63 million). It invests 30 percent of its corpus in very early stage companies with less than $5 million in revenues. The firm seeks to make minority and majority investments. Molten Ventures Plc was founded in 1984 and is based in London, United Kingdom with an additional offices in Dublin, Ireland.
Full GRWXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.